Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Shepherd

Showing results (11-20 of 105) with videos related to

Pageof 11
Sort By:
The American Journal of Geriatric Cardiology|March 11, 2008
Monotherapy vs combination therapy for dyslipidemia in the elderlyJames Shepherd
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 17, 2020
Preventing COVID-19 Collateral DamageJames Shepherd, Gerald Friedland
Atherosclerosis. Supplements|April 27, 2002
Lipid-lowering--translating evidence into benefitsJames Shepherd, Philip Barter
European Heart Journal|June 24, 2005
Lipids and CVD management: towards a global consensusChristie Ballantyne, Bruce Arroll, James Shepherd
Journal of the American College of Cardiology|May 31, 2008
Association of the 719Arg variant of KIF6 with both increased risk of coronary events and with greater response to statin therapyOlga Iakoubova, James Shepherd, Frank Sacks
Current Medical Research and Opinion|June 23, 2005
Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus PanelJames Shepherd, John Betteridge, Luc Van Gaal, et al.
Drugs & Aging|March 19, 2003
Statin therapy in the elderly: does it make good clinical and economic sense?Moira M B Mungall, Allan Gaw, James Shepherd
Emergency Radiology|November 26, 2010
Are you ready?--lessons learned from the Fort Hood shooting in TexasJames Shepherd, Clint Gerdes, Michael Nipper, et al.
Presse Medicale (Paris, France : 1983)|November 4, 2004
[Hypercholesterolemia, the future of drug associations]James Shepherd, Jean-Pierre Bassand, Hugues Milon, et al.
AIDS (London, England)|October 27, 2016
Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemicAmber Kunkel, Forrest W Crawford, James Shepherd, et al.
Pageof 11

Showing results (11-20 of 105) with videos related to

Sort By:
Pageof 11
The American Journal of Geriatric Cardiology|March 11, 2008
Monotherapy vs combination therapy for dyslipidemia in the elderlyJames Shepherd
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 17, 2020
Preventing COVID-19 Collateral DamageJames Shepherd, Gerald Friedland
Atherosclerosis. Supplements|April 27, 2002
Lipid-lowering--translating evidence into benefitsJames Shepherd, Philip Barter
European Heart Journal|June 24, 2005
Lipids and CVD management: towards a global consensusChristie Ballantyne, Bruce Arroll, James Shepherd
Journal of the American College of Cardiology|May 31, 2008
Association of the 719Arg variant of KIF6 with both increased risk of coronary events and with greater response to statin therapyOlga Iakoubova, James Shepherd, Frank Sacks
Current Medical Research and Opinion|June 23, 2005
Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus PanelJames Shepherd, John Betteridge, Luc Van Gaal, et al.
Drugs & Aging|March 19, 2003
Statin therapy in the elderly: does it make good clinical and economic sense?Moira M B Mungall, Allan Gaw, James Shepherd
Emergency Radiology|November 26, 2010
Are you ready?--lessons learned from the Fort Hood shooting in TexasJames Shepherd, Clint Gerdes, Michael Nipper, et al.
Presse Medicale (Paris, France : 1983)|November 4, 2004
[Hypercholesterolemia, the future of drug associations]James Shepherd, Jean-Pierre Bassand, Hugues Milon, et al.
AIDS (London, England)|October 27, 2016
Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemicAmber Kunkel, Forrest W Crawford, James Shepherd, et al.
Pageof 11